Concepedia

Author

Nan Mou

Tianjin Medical University

Also Known As

N Mou, Nan Mou

23

Publications

241

Citations

8

H-Index

8

Concepts

All Affiliations

Tianjin Medical UniversityTianjin First Center HospitalArmy Medical UniversitySouthwest HospitalCity Of Hope National Medical Center
NM

About

Nan Mou is an author at Tianjin Medical University specializing in microbiology, drug resistance, and pathogenesis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

1

1

33

2

Medicine

1

1

33

3

Microbiology

1

1

33

4

Clinical Microbiology

1

1

33

5

Drug Resistance

1

1

33

Nan Mou

×

8

Publications

224

Citations

8

H-Index

YearCitations

Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant

Pengjiang Liu, Meijing Liu, Cuicui Lyu,

Frontiers in Oncology

2020

57

Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia

Jia Wang, Nan Mou, Zhenxing Yang,

British Journal of Haematology

2020

50

Luteolin attenuates the pathogenesis of Staphylococcus aureus by interfering with the agr system

Yuan Qian, Wei Feng, Yu Wang,

Microbial Pathogenesis

2022

33

Humanized anti‐CD19 chimeric antigen receptor‐T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection

Rui Cui, Cuicui Lyu, Qing Li,

Hematological Oncology

2020

24

The expression and significance of efferocytosis and immune checkpoint related molecules in pancancer samples and the correlation of their expression with anticancer drug sensitivity

Lin Cheng, Bangbi Weng, Changsheng Jia,

Frontiers in Pharmacology

2022

18

Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors

Qi Ai, Fanlu Li, Siyi Zou,

Frontiers in Immunology

2023

15

Cyclic RGD-Functionalized pH/ROS Dual-Responsive Nanoparticle for Targeted Breast Cancer Therapy

Pu Yao, Xiaowen Wang, Qianmei Wang,

Pharmaceutics

2023

14

Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk

Cuicui Lyu, Rui Cui, Jia Wang,

Frontiers in Oncology

2021

13

Page 1